The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product,
Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy
(CIPN) among non-metastatic breast, colorectal, uterine and ovarian cancer patients who
received neoadjuvant or adjuvant therapy that included neurotoxic chemotherapeutic agents.